Kniftig schreef op 20 juli 2012 14:09:
Zontomaatje:
The observed beneficial effects of rhC1-INH treatment on tissue injury 20 min into severe hypotension present an attractive model of low-volume resuscitation, particularly in situations with a restrictive medical logistical footprint.
journals.lww.com/shockjournal/Abstrac...Verder kan je wel degelijk opmaken dat er een grotere omzetten te verwachten valt dar waar artsen signaleren dat HAE wellicht een onderschat probleem is en Ruconest een goede therapeutische behandeling biedt (geen genezende dus, maar dat doen de plasma's ook niet).
The medical need for treatment of these attacks may be underestimated. Treatment with rhC1INH constitutes a therapeutic option for acute peripheral hereditary angioedema attacks.
www.ncbi.nlm.nih.gov/pubmed/22748405Bewezen voordelen Ruconest tov plasma:
Asphyxiation as a result of upper airway obstruction in bradykinin-mediated angioedema has a mortality rate of up to 30%. Hereditary angioedema (HAE) type III presents the same symptoms as types I and II, which are both associated with C1 Inhibitor (C1Inh) deficiency. In HAE type III, C1Inh and C4 assays are normal and treatment usually involves human plasma-derived C1Inh (pdC1Inh) and icatibant. We describe here the first treatment of moderate and severe attacks using recombinant human C1Inh (rhC1Inh) in a 27-year old female with HAE type III. A first attack, consisting of severe abdominal symptoms and vomiting, occurred at age 25. After 10 months of remission, the patient experienced frequent abdominal attacks (1 to 2 per week) often with peripheral oedema that required two emergency unit visits. Prophylactic treatment with pdC1Inh 3000 IU/week and tranexamic acid 3g/day was started, with additional pdC1Inh 20 IU/kg (administered by a health care professional) or icatibant (by self-administration) for severe attacks and tranexamic acid for non-severe attacks. We treated 3 attacks with rhC1Inh 50 IU/kg. The first moderate-to-severe abdominal attack (VAS 5) occurred in hospital. rhC1Inh was administered 16 hours after attack onset, and symptoms resolved completely within 30 minutes. The second was a severe combined attack, at home, with facial oedema, epigastric and chest pain (VAS 9). rhC1Inh, administered 9 hours after onset, resolved symptoms within 30 min. The third attack, which also occurred at home, was severe and characterized by laryngeal oedema and chest pain. rhC1Inh was administered 2 hours after onset, and laryngeal oedema and chest pain resolved completely after 30 min and 1 hour 30 min, respectively. Prior to rhC1Inh treatment, and despite long-term prophylaxis with pdC1Inh, the patient experienced 1–2 attacks per week. No attacks occurred during the 8 days following rhC1Inh treatment. With pdC1Inh and icatibant, a slight residual pain remained after treatment of abdominal attacks, which was not the case with rhC1Inh. However, these findings remain to be further investigated in wider cohort and confirmed in a clinical study. rhC1Inh is not approved for self-administration; additionally, patients must be negative for IgE against rabbit dander prior initiating treatment, as the drug is produced in transgenic rabbits. Although very preliminary, this first experience suggests that rhC1Inh may be used successfully in patients with HAE type III.
www.eaaci2012.com/SiteSpecific/Eaaci2...Dus ik kan niet echt meegaan in jullie stellingen.
Overigens ben ik wel benieuwd van Meelezer.
Hoe zit het met de prijsverschillen tussen Rhucin en Ruconest, waar komt dat verschil vandaan? Is dat louter winst, kan ik mij niet voorstellen namelijk?